Clinical Trial Update: OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events [Phase 3]

View source ↗

Summary

This entry notes that Amgen's Phase 3 OCEAN(a)-PreEvent program is recruiting to evaluate olpasiran for prevention of first major cardiovascular events related …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• Olpasiran (olpasiran)

Snippet

Sponsor: Amgen | Conditions: Cardiovascular Disease | Phase 3 | Status: RECRUITING